Ads
related to: latest treatments for overactive bladder
Search results
Results From The WOW.Com Content Network
Overactive bladder isn’t a disease but rather a syndrome defined by a collection of symptoms, says Jennifer Linehan, MD, a urologist and associate professor of urologic oncology at the John ...
Percutaneous tibial nerve stimulation (PTNS), also referred to as posterior tibial nerve stimulation, is the least invasive form of neuromodulation used to treat overactive bladder (OAB) and the associated symptoms of urinary urgency, urinary frequency and urge incontinence.
Overactive bladder affects approximately 11% of the population and more than 40% of people with overactive bladder have incontinence. [5] [6] Conversely, about 40% to 70% of urinary incontinence is due to overactive bladder. [7] Overactive bladder is not life-threatening, [1] but most people with the condition have problems for years. [1]
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.
For premium support please call: 800-290-4726 more ways to reach us
Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder. [1] [5] [6] Vibegron is a selective beta-3 adrenergic receptor agonist. [1] The most common side effects include headache, urinary tract infection, common cold, diarrhea, nausea, and upper respiratory tract infection. [5]
Ads
related to: latest treatments for overactive bladder